Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists reduce hospitalization for heart failure, chronic kidney disease, and atherosclerotic cardiovascular disease in patients with type 2 diabetes.
If you have type 2 diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors or GLP-1 RAs. These drugs do more than lower blood sugar; they protect your heart and kidneys, reducing the risk of hospitalization and death.
StrongSupportsHIGH confidence
With development of SGLT2 inhibitors (sodium glucose cotransporter 2 inhibitors) and GLP-1RA (glucagon-like peptide-1 receptor agonist), the clinical benefits also include risk reduction of diabetes-related complications (hospitalization for heart failure, chronic kidney disease, atherosclerotic cardiovascular disease)...
Why this rating
Based on multiple cited large-scale clinical trials (DAPA-CKD, DAPA-HF, etc.).
Source
Extent of Role: Anti-Diabetic Medications
Jun Hwa Hong · Journal of Korean Diabetes · 2022
DOI 10.4093/jkd.2022.23.3.153
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →